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Summary
Objective: Osteoarthritis (OA) is the most common form of arthritis and the second most common cause of long-term disability among middle-
aged and older adults in the United States. Methylsulfonylmethane (MSM) is a popular dietary supplement used as a single agent and in com-
bination with other nutrients, and purported to be beneﬁcial for arthritis. However, there is paucity of evidence to support the use of MSM.
Methods: A randomized, double-blind, placebo-controlled trial was conducted. Fifty men and women, 40e76 years of age with knee OA pain
were enrolled in an outpatient medical center. Intervention was MSM 3 g or placebo twice a day for 12 weeks (6 g/day total). Outcomes in-
cluded the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician global as-
sessments (disease status, response to therapy), and SF-36 (overall health-related quality of life).
Results: Compared to placebo, MSM produced signiﬁcant decreases in WOMAC pain and physical function impairment (P< 0.05). No notable
changes were found in WOMAC stiffness and aggregated total symptoms scores. MSM also produced improvement in performing activities of
daily living when compared to placebo on the SF-36 evaluation (P< 0.05).
Conclusion: MSM (3 g twice a day) improved symptoms of pain and physical function during the short intervention without major adverse
events. The beneﬁts and safety of MSM in managing OA and long-term use cannot be conﬁrmed from this pilot trial, but its potential clinical
application is examined. Underlying mechanisms of action and need for further investigation of MSM are discussed.
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SocietyIntroduction
Osteoarthritis (OA) is the leading cause of disability, limiting
everyday activities of more than 7 million Americans1, and is
associated with restrictions on quality of life2. The demand
for arthritis pain control has resulted in the widespread
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Received 2 May 2005; revision accepted 8 October 2005.28use of palliative drugs, e.g., nonsteroidal anti-inﬂammatory
drugs (NSAIDs), acetaminophen, and cyclooxygenase-2
(COX-2) inhibitors3,4, surgical interventions5, and in recent
years, the use of complementary and alternative medicine
(CAM)6. Additional treatment options are being actively
sought out by patients as discontinuation of COX-2 drugs
rises due to concerns of safety.
A dietary supplement with increasing use is methylsulfo-
nylmethane (MSM) often in combination with glucosamine
and chondroitin sulfate, which as opposed to MSM has nu-
merous efﬁcacy trials supporting its use in OA7e9. MSM is
popularly used for arthritic and rheumatic pain; in 2003,
the retail sales of MSM as a single ingredient were $115
million10. MSM is a naturally occurring organosulfur mole-
cule and a putative methyl donor. MSM is the ﬁrst oxidized
metabolite of dimethylsulfoxide (DMSO). In the tropo-
sphere, DMSO is a byproduct of phytoplankton and algae
decay. In commercial production, MSM is synthesized by
reacting DMSO and hydrogen peroxide, which yields6
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ingested DMSO is metabolized into MSM11. A recent study
showed that MSM was found in human cerebrospinal ﬂuid
and plasma at 0e25 mmol/l concentrations12. Because of
MSM’s sulfur content, it is used by the body to maintain nor-
mal connective tissues. MSM may have anti-inﬂammatory
activities, chemopreventive properties, prostacyclin (PGI2)
synthesis inhibition, anti-atherosclerotic action, salutary ef-
fect on eicosanoid metabolism, and free radical scavenging
activity13e15. In murine models, MSM was shown to effect
inﬂammatory conditions such as rheumatoid arthritis and lu-
pus16,17. One randomized controlled trial of MSM and OA
has been published18. In Usha and Naidu’s18 12-week trial
(n¼ 118), patients with knee OA received either 1.5 g MSM,
1.5 g glucosamine sulfate, 1.5 g MSM plus glucosamine
sulfate, or placebo; signiﬁcant decreases in the Lequesne
Index were reported with MSM, glucosamine sulfate, and
their combination (P< 0.05). The authors reported a 33%
decrease in pain in the MSM group; joint mobility, swelling,
global evaluation, and walking time also improved.
MSM safety and toxicity clinical studies have not been
published. Acute and subchronic animal toxicity studies
using single dose of 2 g/kg and daily doses of 1.5 g/kg
MSM for 90 days showed no adverse events, organ patholo-
gy or mortality19. These doses are considered ﬁve to seven
times the maximum dose used in humans. MSM is generally
considered safe, and listed on The Arthritis Foundation’s
Guide to Alternative Therapies for OA with a cautionary
note on lack of research20. There have been unconﬁrmed re-
ports of mild adverse effects from oral use of MSM including
gastrointestinal (GI) symptoms, headaches, ampliﬁed ef-
fects of blood thinning drugs resulting in easy bruising and
blood in stool, increased blood pressure, increased hepatic
enzymes, and insomnia if taken at bedtime21. However,
there are no clinical studies on adverse effects, changes in
blood chemistry, safety monitoring data or possible subclin-
ical neurotoxicity symptoms of MSM. MSM is currently sold
in over 52 different products as a single agent in capsule,
caplet, lotion and cream forms, and in more than 30 different
products in combination with other dietary supplements (glu-
cosamine and chondroitin sulfate being the most common).
MSM is readily available at health food stores and on the In-
ternet with alarmingly little guidance on safety and how to
take the supplement. Investigation is needed on MSM efﬁca-
cy and safety in the dosages commonly used by practitioners
and consumers alike to treat OA, which are higher than the
dosage used in Usha’s study. Equally signiﬁcant is the public
service provided by testing a highly prevalent dietary supple-
ment to contribute to the scientiﬁc repertoire of this new sup-
plement that is not regulated by the Food and Drug
Administration (FDA). Considering the popularity of MSM
and purported improvements in OA pain, additional efﬁcacy
and safety trial of MSMwill thus be valuable in advising prac-
titioners and patients in the appropriate use, if any, of MSM
for arthritis pain management. Although a murine model re-
ported decreasing joint degeneration22, due to the prelimi-
nary design and short intervention period, treatment
responses were limited to OA symptoms, and did not include
radiographic changes of the joints following intervention.
Methods
PARTICIPANTS
The study was conducted in accordance with the Decla-
ration of Helsinki and approved by the Institutional ReviewBoard at Southwest College of Naturopathic Medicine. Writ-
ten consents were obtained prior to enrollment. Knee OA
was selected as opposed to hip or hands to evaluate a single
joint for a preliminary efﬁcacy clinical trial. Study inclusion
criteria included men and women >40 years diagnosed
with knee OA according to modiﬁed criteria of the American
College of Rheumatology (ACR)23,24; ACR functional
class I, II or III25; radiographic conﬁrmed Kellgrene
Lawrence grades 2e3 (mild to moderate osteophytes and
joint space narrowing, previous 3 years)26; regular arthritis
pain (arthritis pain in most days) for 3 months or more;
>40 mm arthritis pain rating of target knee (100 mm visual
analogue scale (VAS)); and >2 rating on patient global as-
sessment (GA) of overall arthritis disease status (ﬁve-point
Likert scale). Patients were not required to be asymptomatic
in the other joints. Study exclusion criteria included any
other type of arthritis; rheumatoid or inﬂammatory arthritis;
ﬁbromyalgia or other chronic pain syndrome; arthroscopy
or intra-articular corticosteroids/hyaluronic acid injections
in the previous 3 months; concurrent anti-coagulant/anti-
platelet drugs, corticosteroids or narcotic pain killers use;
history of epilepsy or bleeding disorders; gastric ulcers; renal
or hepatic disease; uncontrolled hypertension, or body mass
index (BMI) >45 kg/m2. A washout period of 7 days was re-
quired for NSAIDs users. Discontinuing the use of common
CAM therapies for arthritis (e.g., glucosamine, chondroitin
sulfate, bromelain, DMSO, acupuncture) was required for
7 days prior to enrollment.
ENROLLMENT AND RANDOMIZATION PROCEDURES
Patients were recruited from the Phoenix metropolitan
area using newspaper advertisements, ﬂyers at local clinics,
and press releases. Initial screening was conducted over
the phone or in person. Qualiﬁed patients (n¼ 50) were as-
signed to MSM (n¼ 25) or placebo (n¼ 25) in a 12-week
randomized, double-blind, placebo-controlled trial using
computer-generated random numbers (Fig. 1). The genera-
tion of numbers and assignments were provided by different
research staff not involved with patient contacts or data col-
lection. Rescue analgesic, 325 mg acetaminophen tablets
(100 tablets), was provided with instructions for use with in-
tolerable pain and to not exceed taking 2.6 g/day. To mon-
itor compliance and adverse events, weekly and biweekly
phone calls to patients were made during the 12 weeks by
the research staff.
MSM DOSAGE AND PREPARATION
A dosage of 6 g/day was selected based on common clin-
ical and over-the-counter uses of MSM. A 1-week, stepwise
approach to the full dose was undertaken. Week 1, started
with 2 g/day in two divided doses for 3 days, and then in-
creased to 4 g/day for 4 days. Week 2, increased to 6 g/day.
Patients were instructed to take with food, and to avoid tak-
ing them at bedtime. Distilled MSM microprill (OptiMSM,
Cardinal Nutrition, Vancouver, WA) in 1 g caps was used.
Purity of MSM was conﬁrmed to be 99.9% by high-resolu-
tion gas chromatography. DMSO content was <0.05%.
The placebo consisted of inert ingredients and was indistin-
guishable in color, size and taste compared to the MSM.
Test materials were certiﬁed to be free of microbiological
contamination. Heavy metal analysis by graphite furnace
atomic absorption spectrophotometry and cold vapor analy-
sis veriﬁed no quantiﬁable lead, arsenic, cadmium, alumi-
num, or mercury. The analytical tests were validated for
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analysis from the manufacturer. These assays were per-
formed by an independent, third-party laboratory as part
of the standard quality control in the manufacture of the
raw ingredient MSM.
EFFICACY EVALUATIONS
The knee with the worst arthritis pain (target joint) at
screening was the joint evaluated for efﬁcacy. Primary end-
points were the composite subscales in the Western On-
tario and McMaster University Osteoarthritis Index VAS
(WOMAC version 3.1) on pain (ﬁve questions), stiffness
(two questions), physical function (17 questions), and ag-
gregated total symptoms (24 questions)27,28. The WOMAC
was scored from 0 mm to 100 mm (0¼ no pain, 100¼worst
pain), and collected at baseline (following the washout period
of 7 days), 2, 4, 8 and 12 weeks. Secondary endpoints were
the patient GA, physician GA, and SF-36 (version 2) for the
overall health-related quality of life, collected at baseline
and 12 weeks. The patient GA and physician GA were
scored on a ﬁve-point Likert scale for overall arthritis dis-
ease status (0¼ very well, 1¼well, 2¼moderate, 3¼ poor,
4¼ very poor) and response to therapy (0¼ excellent re-
sponse, 1¼ good response, 2¼moderate response,
3¼ slight response, 4¼ no response). SF-36 was chosen
for its previous application in a variety of diseases including
OA efﬁcacy studies29e31. Responses to the 36 items are
categorized into nine domains: physical functioning, role
physical, bodily pain, general health, vitality, social function-
ing, role emotional, mental health, and reported health tran-
sition. Scores ranged from 0 to 100 with higher scores
indicating better state of health and quality of life.
To investigate MSM’s potential activity, although not com-
monly evaluated in OA studies, serum homocysteine, high
sensitive C-reactive protein (CRP), erythrocyte
Assessed for eligibility (n=247)
Randomized (n=50)
 Excluded (n=197) 
Not meet criteria (n=139)
Clinic distance (n=48)
Refused to stop alternative  
therapies (n=7)
Refused to stop drugs (n=3) 
MSM Group (n=25) Placebo Group (n=25)
Discontinued; lack of   
response (n=2)
Discontinued; adverse 
event (n=1) 
Lost to follow up (n=1)
Discontinued; lack of 
response (n=5) 
Lost to follow up (n=1)
Analyzed (n=21)
Excluded from analysis
(n=0) 
Analyzed (n=19) 
Excluded from analysis
(n=0)
Fig. 1. Patient enrollment and follow-up diagram.sedimentation rate (ESR), and urine malondialdehyde
(MDA) were measured at baseline and 12 weeks. Hyperho-
mocysteinemia is associated with ischemic cardiovascular
conditions; and reducing homocysteine with micronutrients
has been demonstrated to decrease heart disease32. Ho-
mocysteine is metabolized by a remethylation pathway
(transfer of methyl by methylcobalamin or betaine [trimethyl-
glycine]) generating methionine, and a transsulfuration
pathway which degrades homocysteine into cysteine and
then taurine33. Since MSM is a putative methyl donor, its
activity as a co-factor in reducing homocysteine levels
was tested. To monitor any anti-inﬂammatory activities of
MSM, as suggested from empirical and published literature,
CRP and ESR were tested. The MDA was measured to ex-
amine the possible antioxidant effect of MSM, which has
also been suggested15. Thus, these lab tests were included
in the pilot clinical trial to explore MSM’s mechanisms of ac-
tion. Other endpoints included the use of rescue analgesics
and compliance with MSM regimen.
ADVERSE EVENTS EVALUATIONS
Laboratory tests, questionnaires, blood pressure, weight,
BMI, and other vitals were collected at baseline and 12
weeks. The laboratory tests included hematology (complete
blood counts and differential white blood cells), clinical
chemistry (renal and hepatic functions), fasting lipid proﬁle,
urinalysis, and stool occult blood test. The questionnaires
included the standard GI symptoms and modiﬁed neuroto-
xic symptoms using a four-point Likert scale ranging from
0 to 3 (0¼ no, 1¼mild, 2¼moderate, 3¼ severe). Ques-
tions related to changes in blood clotting were also inclu-
ded. Modiﬁcations were made on neurotoxicity
questionnaires used in drug trials for application in our
study34e36: cognitive function (fatigue, concentration, slow-
ing, memory, motor coordination and language), peripheral
neurological symptoms (sensory disturbance and muscle
weakness), and other symptoms (insomnia, headache
and blurred vision).
STATISTICAL ANALYSIS
The intent-to-treat analysis was performed using SPSS
(version 11.0) software. The changes from baseline to 12
weeks between treatment and placebo groups were consid-
ered signiﬁcant for Student’s t test P values< 0.05 at the
95% conﬁdence level. Estimated sample size was calculat-
ed using 80% power with a two-sided (tailed) test, alpha of
0.05 to detect a 25% improvement in VAS arthritis pain
score from baseline to 12 weeks in the MSM treated group,
indicating that 22 patients were required37,38. The estimated
variance and power calculation were based on previous
knee OA pilot trial publications39,40. With an anticipated
10% attrition rate, 25 patients per group were adequate to
meet the sample size requirement.
Results
DEMOGRAPHIC PROFILE
About 90% of patients were in the ACR classes I and II,
and 5% in class III (Table I). Average arthritis duration
was about 6 years. The mean pain level was 55 mm in
the placebo group and 58 mm in the MSM group. Thirty-
seven percent and 38% of patients in the placebo group
and MSM group, respectively, used some type of NSAIDs,
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taining products. The patients with history of MSM intake
used less than 1 g/day, were inconsistent in daily use
and /or used MSM predominantly in the form of combination
dietary supplement products rather than as monotherapy,
and the quality of MSM was not determined. Also, one
patient in the MSM group and two patients in the placebo
group were using glucosamine plus chondroitin sulfate prior
to study enrollment. Expectation bias and confounding var-
iables of participating in a study testing MSM were therefore
likely to be minimal (patients could not have discerned the
individual effects of MSM when taken in products containing
many other active ingredients, e.g., glucosamine, chondroi-
tin sulfate, herbs, vitamins, and minerals). No major
differences in the arthritis disease status and other charac-
teristics were found between the MSM and placebo groups
at enrollment. The baseline patient proﬁles suggest that any
changes in response to the intervention were not due to
variability of patients in the two groups. Compliance with
pill taking and other study instructions were obtained from
the majority of patients. In the MSM group 89.5% and in
the placebo group 90.5% took at least ﬁve pills a day.
The study bottles were returned at the end of treatment,
and the number of pills remaining was counted.
EFFICACY RESULTS
The results of WOMAC are listed in Table II. The primary
endpoint pain changes at 12 weeks in the MSM group were
signiﬁcantly greater than in the placebo group, P¼ 0.041.
The changes in the physical function in the MSM group
Table I
Demographic profile of patients and arthritis characteristics
MSM (n¼ 21) Placebo (n¼ 19)
Sex (%)
Men 42.9 31.6
Women 57.1 68.4
Age, mean (years) 56.6 (SD¼ 8.6) 55.6 (SD¼ 8.7)
Ethnicity (%)
White/non-Hispanic 100 89.5
Asian/Paciﬁc islander 0 10.5
NSAID use (%) 38.1 36.8
MSM use (%) 28.6 26.3
DMSO use (%) 9.5 5.3
Glucosamine plus chondroitin
sulfate use (%)
4.8 10.5
ACR functional capacity
classiﬁcation (%)
I 23.8 26.3
II 71.4 68.4
III 4.8 5.3
KellgreneLawrence grade (%)
2 61.9 57.9
3 38.1 42.1
Arthritis duration,
mean (years)
5.8 (SD¼ 5.5) 5.9 (SD¼ 5.2)
Pain VAS, mean S.E.M.
(0e100 mm, VAS)
58.0 5.5 55.1 5.8
Patient GA of disease status,
mean S.E.M. (0e4, Likert)
3.0 0.1 2.8 0.2
Physician GA of disease
status, mean S.E.M.
(0e4, Likert)
2.8 0.2 2.5 0.1were also greater than in the placebo group at 12 weeks,
P¼ 0.045. The pain and physical function mean decreases
from baseline to 4, 8 and 12 weeks in the MSM group were
greater compared to the placebo group (Figs. 2 and 3). The
changes in stiffness and aggregated total symptoms after
12 weeks of treatment were not signiﬁcant between the
two groups, P> 0.05. There were changes found in the pla-
cebo group. The differences between the MSM and placebo
groups were relatively small in the WOMAC subscales. In
the MSM group pain decreased by 14.6 mm (25.1%), and
in placebo it decreased by 7.3 mm (13.2%) at 12 weeks.
The difference in pain improvement was 7.3 mm (12%) be-
tween the MSM and placebo groups. For physical function,
stiffness and total symptoms, the decreases in MSM group
were 15.7 mm (30.4%), 10.1 mm (19.7%), and 13.4 mm
(25.1%) and the decreases in placebo group 8.8 mm
(16.7%), 6.5 mm (11.7%), and 7.5 mm (13.8%), respectively.
The differences between the groups were 6.8 mm (13.7%),
3.6 mm (8.0%), and 5.9 mm (11.3%) at 12 weeks, respec-
tively. The patient GA and physician GA of overall arthritis
disease status changes at 12 weeks in the MSM
group and placebo group were not signiﬁcant, P> 0.05
(Table II). However, the changes in disease status suggest
a trend toward improvement in the treatment group. The
patient GA and physician GA of response to therapy
also showed no major differences. In the SF-36 quality of
life results, of the nine domains, only the role physical
domain at 12 weeks in the MSM group was signiﬁcant
with a mean change of 16.45 (SD¼ 20.84), P¼ 0.021.
While in the placebo group, a mean change of 12.48
(SD¼ 23.17) was observed on the role physical domain,
P¼ 0.175. No notable changes were found in the other
eight domains, P> 0.05. There were no appreciable differ-
ences in the use of rescue analgesics; the mean use was
37.9 (SD¼ 25.7) tablets over 12 weeks in the placebo
group compared to 27.4 tablets (SD¼ 21.2) in the MSM
group.
LAB MONITORING
Hematology, clinical chemistry and urinalysis did not
have any abnormal changes from baseline to 12 weeks.
There were no major changes in the complete blood counts,
differential white blood cell counts, hepatic and renal func-
tions, lipid proﬁles, BMI, vitals, stool occult test, swelling
or tenderness of the target knee joints. Three patients did
have positive hemoccult tests at 12 weeks, two in the placebo
group and one in the MSM group. The hemoccult was
repeated 2 weeks later; the results were negative. Homo-
cysteine (P¼ 0.004) and urine MDA (P¼ 0.010) were
the only two laboratory markers with signiﬁcant differences
at 12 weeks between the MSM and placebo groups
(Table III).
ADVERSE EVENTS
The incidences of GI and other side effects included
bloating, constipation, indigestion, fatigue, concentration is-
sues, insomnia, and headache (Table IV). These symptoms
were minor, without complications, and did not interfere with
daily activity or require treatment. Patients in the MSM and
placebo groups reported the symptoms in comparable fre-
quency. Of the 50 patients enrolled, 40 completed the
study: 21 (84%) in the MSM group and 19 (76%) in the pla-
cebo group. The majority of patient withdrawals were report-
edly due to lack of perceived response to therapy, two in the
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WOMAC, patient and physician GAs
MSM (n¼ 21) Placebo (n¼ 19) Between group
difference at
12 weeks
P values
Baseline
mean S.E.M.
12 weeks
mean S.E.M.
Change S.E.M. Baseline
mean S.E.M.
12 weeks
mean S.E.M.
Change S.E.M.
WOMAC (0e100 mm, VAS)
Pain 58.0 5.5 43.4 4.6 14.6 1.3 55.1 5.8 47.9 4.8 7.3 3.3 0.041*
Stiffness 51.2 5.4 41.1 4.8 10.1 2.6 55.2 6.2 48.7 6.8 6.5 2.4 0.320
Physical function 51.5 4.5 35.8 3.2 15.7 2.0 52.9 5.9 44.1 5.1 8.8 2.7 0.045*
Total symptoms 53.6 4.9 40.1 3.9 13.4 1.7 54.4 5.6 46.9 5.2 7.5 2.5 0.054
Patient GA (0e4, Likert)
Disease status 3.0 0.1 2.5 0.2 0.5 0.2 2.8 0.2 2.5 0.2 0.3 0.2 0.549
Physician GA (0e4, Likert)
Disease status 2.8 0.2 2.5 0.1 0.3 0.1 2.5 0.1 2.3 0.2 0.2 0.2 0.447
*Between group differences in the MSM and placebo evaluated using the Student’s t test. The changes were considered signiﬁcant for
P< 0.05. The changes in the primary endpoints WOMAC pain and physical function at 12 weeks were signiﬁcant between the MSM and pla-
cebo groups.MSM group and ﬁve in the placebo. One patient dropped
out in each group due to loss to study follow-up. One patient
in the MSM group discontinued prematurely due to an ad-
verse event in the ﬁrst 2 weeks. The patient reported having
neck and back pain that were similar in symptoms to a pre-
vious kidney infection. Clinical examination and lab tests of
the patient showed that there was no infection or other
major health problems. The patient also reported worsening
of arthritis pain and joint swelling.
Discussion
In this trial, MSM at 3 g twice a day for 12 weeks pro-
duced improvement in two of the three WOMAC subscales,
pain and physical function, P< 0.05. Comparable efﬁcacy
results have been reported in the literature but for different
MSM dosages. The dosage we used was four times the
dosage of Usha’s study, but in our study arthritis pain de-
creased by 25.1% compared to 33% decrease seen in
Usha’s study18. The small sample size with variations in ar-
thritis pain and other patient characteristics confounding the
data may have contributed to the smaller decrease
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Fig. 2. WOMAC pain changes from baseline to 2, 4, 8 and 12
weeks.observed in our study compared to Usha’s study. An unpub-
lished trial (n¼ 16) of MSM for arthritis pain, 2.25 g, also re-
ported some improvement41. The changes in WOMAC
subscales, pain, physical function, stiffness, and total symp-
toms in the placebo group by 7.3 mm (13.2%), 8.8 mm
(16.7%), 6.5 mm (11.7%), and 7.5 mm (13.8%), respectively,
at 12 weeks are worthy of discussion. The changes in the
placebo group and the small differences between the two
groups indicate that the effect of MSM was modest. Thus,
while improvements in pain and physical function were
shown to be statistically signiﬁcant, the clinical signiﬁcance
of these symptoms improvements remains uncertain. The
overall trend in WOMAC subset decreases does show ben-
eﬁts of MSM, and further evaluation for practical application
is justiﬁed. Another noteworthy ﬁnding is that the WOMAC
subsets continued to decline at 12 weeks, suggesting that
the full effects of MSM were not captured during the rela-
tively short intervention; a longer study is needed to deter-
mine if and when the effects of MSM would plateau. The
patient GA and physician GA trends correlated with those
observed with the WOMAC in the MSM group. However, ef-
ﬁcacy changes in previously published COX-2 drug trials
are greater, e.g., celecoxib decreased WOMAC pain,
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Fig. 3. WOMAC physical function changes from baseline to 2, 4, 8
and 12 weeks.
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Lab markers: total cholesterol, homocysteine, CRP, ESR and urine MDA
MSM (n¼ 21) Placebo (n¼ 19) Between group
difference at
12 weeks
P values
Baseline
mean S.E.M.
12 weeks
mean S.E.M.
Change S.E.M. Baseline
mean S.E.M.
12 weeks
mean S.E.M.
Change S.E.M.
Total cholesterol (mg/dL) 213.5 10.4 203.5 8.5 10.0 3.2 201.5 9.8 193.7 9.9 7.8 2.7 0.607
Homocysteine (mmol/L) 8.0 0.4 7.2 0.4 0.8 0.2 8.3 0.4 8.6 0.5 0.4 0.3 0.004*
CRP (mg/L) 1.6 0.3 1.5 0.2 0.1 0.2 2.3 0.4 2.3 0.4 0.1 0.2 0.540
ESR (mm/h) 6.4 1.2 5.8 0.9 0.6 0.7 5.7 1.3 6.2 1.1 0.4 0.6 0.324
Urine MDA (mmol/L) 16.7 1.0 14.3 0.8 2.4 0.9 15.0 1.0 16.3 0.9 1.3 1.0 0.010*
*Between group differences in the MSM and placebo evaluated using the Student’s t test. The changes were considered signiﬁcant for
P< 0.05. The changes in homocysteine and urine MDA at 12 weeks were signiﬁcant between the MSM and placebo groups.stiffness and physical function by 28.6 mm, 27.9 mm, and
24.9 mm, respectively3, and etoricoxib decreased by
22.29 mm, 19.01 mm, and 22.87 mm4, compared to our
MSM trial, which decreased by 14.6 mm, 10.1 mm, and
15.7 mm, respectively. The differences in OA disease char-
acteristics should be noted for these COX-2 studies, where
the patients typically had more severe arthritis compared to
the patients enrolled in our study. Symptoms improved in
WOMAC subsets, particularly pain from 58.0 mm to
43.3 mm at 12 weeks, these values indicate that the pa-
tients were experiencing pain.
MSM has been shown to reduce seasonal allergic rhinitis
symptoms42.MSM’s anti-inﬂammatory activitieswere sought
Table IV
Incidence of patients reporting adverse events based on the GI and
modified neurotoxic symptoms questionnaires
Number (%)
MSM (n¼ 21) Placebo (n¼ 19)
GI symptoms
Bloating 3 (25) 2 (18)
Constipation 2 (17) 2 (18)
Indigestion 1 (8) 1 (9)
Loose stool 0 0
Gas 0 0
Diarrhea 0 0
Stomach pain 0 0
Acid reﬂux 0 0
Heartburn 0 0
Vomiting 0 0
Nausea 0 0
Blood clotting
Bruise easily 0 0
Nose bleeding 0 0
Bleeding (clotting) time longer 0 0
Modiﬁed neurotoxic symptoms
Cognitive function
Fatigue 2 (17) 3 (27)
Concentration 1 (8) 1 (9)
Slowing 0 0
Memory 0 0
Motor coordination 0 0
Language 0 0
Peripheral neurological symptoms
Sensory disturbance 0 0
Muscle weakness 0 0
Others
Insomnia 2 (17) 1 (9)
Headache 1 (8) 1 (9)
Blurred vision 0 0by testing CRP and ESR. These markers are used to predict
chronic conditions such as cardiovascular disease (CVD)
and to monitor inﬂammatory disease processes43,44. In our
study, the high sensitive CRP and ESR showed no changes.
The Centers for Disease Control and the American Heart
Association guidelines onCRP levels deﬁne three categories
of CVD risks: low risk<1.0 mg/L, average risk 1.0e3.0 mg/L,
and high risk >3.0 mg/L44. The baseline mean CRP was
1.6 mg/L in the MSM group and 2.3 mg/L in the placebo
group, indicating average risks for CVD and no acute inﬂam-
mation. The difference in CRP values between the two
groups at baseline was not statistically signiﬁcant
(P> 0.05). However, there were observational clinical differ-
ences in the baseline values between the two groups. This
may be due to the small sample size. Baseline mean
ESR was 6.4 mm/h in the MSM group and 5.7 mm/h in the
placebo group, indicating no acute inﬂammation since
ESR< 30 mm/h is considered normal for our patient age
group45. Thus, the effects of MSM as an anti-inﬂammatory
agent were not determined.
Reduction of lipid peroxidation signiﬁed by MDA levels
has been suggested to be beneﬁcial in patients with long-
term inﬂammatory conditions46. MDA has been evaluated
for mutagenic activity and lipid peroxidation-linked DNA
damages, carcinogenicity and genotoxicity47. The decrease
in urine MDA levels in the MSM group was signiﬁcantly dif-
ferent from placebo, suggesting changes in oxidative stress
with MSM. Although the baseline homocysteine levels were
not elevated, the levels did decrease signiﬁcantly in the
MSM group. The decrease in homocysteine may be due to
the donation of MSM’s two methyl groups. Folic acid and
B vitamins are known to reduce hyperhomocysteinemia
through similar mechanisms48. The decreases in homocys-
teine and MDA suggest potential role of MSM in supporting
metabolic processes requiring methylation, such as antioxi-
dant capacities. The high total cholesterol observed in our
study population (Table III) is not uncommon in OA pa-
tients49,50, and hypercholesterolemia and increased homo-
cysteine concentrations have been reported in chronic
diseases such as CVD51,52. The correlation between oxida-
tive damage and cartilage degeneration in OA has recently
been demonstrated53. Pro-coagulant factors have been
shown to compromise subchondral vasculature, and may
thus accelerate joint damage54. MSM’s effect on homocys-
teine and MDA could potentially exert favorable effects on
hypercoagulation and articular inﬂammation. The role of
oxidative stress, hypercholesterolemia and other dyslipide-
mia in contributing to joint degeneration and pain control
should be explored, and this may provide new treatment
possibilities to hasten progression of cartilage degeneration
and other articular deformities and develop new palliative
292 L. S. Kim et al.: Osteoarthritis pain & MSM clinical trialtreatment options in an integrative approach to OA. For ox-
idative damage, cellular damage and low-grade inﬂamma-
tion found in chronic conditions such as OA and
increasingly evident as we age, diets that are low in simple
carbohydrates, sugar, dairy, and saturated fats shown to
be effective in reducing metabolic syndrome and CVD may
also be helpful in joint protection and pain control in OA55.
Such integrative method of reducing oxidative damage
and inﬂammation, improving antioxidative capacity and met-
abolic markers speciﬁc for OA (e.g., hyperlipidemia, elevated
inﬂammatory markers, and compromised vasculature),
effective palliative controls, and diet modiﬁcations could
address the underlying complex pathophysiology of OA.
Considering the risks associated with COX-2 inhibitor
drugs56,57 and the prevalence of coronary risk factors often
found in patients with OA (e.g., hypercholesterolemia, dys-
lipidemia, postmenopausal women, and older age popula-
tion), providing safe treatment options without life
threatening CV events should receive serious consider-
ation. Preparing guidelines for clinical application of MSM
at this time is difﬁcult, and to make suggestions that
MSM, after only 12 weeks of intervention, is safer than
COX-2 drugs would be inappropriate. However, in lieu of
controversies surrounding the drugs for OA, and the low in-
cidence of major adverse events and some improvements
in pain reported, the possible use of MSM in managing
OA symptoms warrants discussion.
Our trial did not ﬁnd adverse events such as high blood
pressure, changes in blood chemistry, increased bruising,
or bleeding time. However, since patients taking concurrent
anti-coagulant/anti-platelet drugs were excluded from our
study, the effects of MSM interfering with these medications
need further testing. Our study weaknesses include small
sample size and short duration of treatment (12 weeks) re-
sulting in limitations in extrapolating to the target population.
Because of the single enrollment site, majority of partici-
pants were those nearby the clinic which may have further
decreased patient pool size and external validity. Prior his-
tory of MSM intake of unknown MSM quality and dosing
regimen by patients in both the MSM and placebo groups
should be noted in interpreting the outcomes of this prelim-
inary trial for possible inﬂuence of such prior use. Other fac-
tors to consider are narrowed interpretation of toxicity and
adverse events, e.g., inclusion of patients with high blood
pressure and heart disease, which are typically found in
the age group with OA, may have resulted in more inciden-
ces of side effects. Also the adverse events reported by few
of the patients including the one patient who prematurely
discontinued with worsening of joint pain and swelling, call
for further safety studies to identify possible at risk patient
populations contraindicated to take MSM. Our study ﬁnd-
ings are only preliminary, and no doseeresponse guidance
can be determined, e.g., the positive changes at varying
daily dosages, 1.5e6 g, need clariﬁcation for optimum dos-
age appropriate for symptoms control in OA. Based on our
results and previous studies, future research direction for
MSM must include long-term treatments, doseeresponse tri-
als, larger sample sizes, study design with greater extrinsic
value, and preclinical and clinical studies to elucidate bioactiv-
ities of MSM to better understand mechanisms of action.
Equally critical are MSM-drug interaction studies for safety
and toxicity, since the group beneﬁting most from OA palli-
ative drugs is the elderly with co-morbid conditions taking
many different drugs. Future research should also consider
MSM’s possible antioxidant activity (like folic acid and B vi-
tamins) which may be actually beneﬁcial in this population
who has high cholesterol and other CVD risks.Another possibility to explore is combination treatments
for palliative control in arthritis pain, such as recent practice
of NSAID plus acetaminophen58. MSM appears to be less
effective than COX-2 drugs, but its use as an adjuvant
with other treatments for OA could be considered. Critical
appraisal of MSM is complicated by the fact that the stan-
dard drug discovery, safety and efﬁcacy studies from pre-
clinical to phase I, II and III clinical trials are not being
followed for MSM. This is commonly the case for CAM ther-
apies currently in the U.S. Without ﬁrst conducting human
safety, pharmacokinetic and pharmacodynamics studies,
dietary supplements typically undergo phase II efﬁcacy clin-
ical trials because biological agents under CAM do not re-
quire FDA’s Investigational New Drug Application or the
New Drug Application. Since MSM is generally regarded
as safe with no reported serious risks, the animal toxicity
study19, previously published randomized trial18, one un-
published trial41, and other publications combined with ﬁnd-
ings of our trial are encouraging for MSM indication in OA.
Our results support short-term intervention with MSM
when NSAIDs and COX-2 drugs are contraindicated or
when other treatments are ineffective. An approach based
on the literature is to start at 1.5 g/day, then to increase
up to 6 g/day in divided doses, and to discontinue use if
no improvements in arthritis pain are noted in 4 weeks.
Thus, while large, long-term, doseeresponse studies in
a more diverse patient population are warranted, MSM
should be considered in certain OA patient populations.
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